Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 185,946 shares of the company's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the transaction, the executive now owns 18,836,547 shares of the company's stock, valued at $226,038,564. This trade represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Thursday, December 26th, Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95.
• On Wednesday, December 18th, Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV remained flat at $12.00 during trading on Thursday. 3,300,963 shares of the stock were exchanged, compared to its average volume of 5,778,284. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06. The business's 50 day moving average is $11.91 and its two-hundred day moving average is $11.51. The stock has a market capitalization of $8.74 billion, a PE ratio of 2.12 and a beta of 1.25.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $17.93.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently bought and sold shares of ROIV. nVerses Capital LLC acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at about $34,000. Gladius Capital Management LP bought a new stake in Roivant Sciences in the third quarter worth approximately $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences in the second quarter valued at approximately $36,000. US Bancorp DE boosted its holdings in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth approximately $53,000. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.